STAAR Surgical Q4 sales miss estimates

Reuters03-04

<a href="https://laohu8.com/S/STAA">STAAR Surgical</a> Q4 sales miss estimates

Overview

Vision correction firm's Q4 net sales rose 18.1% yr/yr but missed analyst expectations
Net loss for Q4 narrowed compared to the previous year

Outlook

STAAR expects modest growth in China's in-market volume demand in 2026

Result Drivers

CHINA SALES - Growth in China drove overall net sales increase, despite inventory management challenges
GROSS MARGIN IMPROVEMENT - Gross margin rose due to cost reductions and timing of cost recognition from previous shipments

Company press release: ID:nBw6WVKSra

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Sales	Miss	$57.80 mln	$75.37 mln (9 Analysts)
Q4 EPS		-$0.37
Q4 Net Income		-$18.31 mln
Q4 Gross Margin		75.70%
Q4 Gross Profit		$43.74 mln
Q4 Operating Income		-$22.84 mln

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 10 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for STAAR Surgical Co is $22.00, about 15.5% above its March 2 closing price of $19.05

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616371007?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 05:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616371007","market":"nz","top_or_hot":-1,"title":"STAAR Surgical Q4 sales miss estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/STAA\">STAAR Surgical</a> Q4 sales miss estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Vision correction firm's Q4 net sales rose 18.1% yr/yr but missed analyst expectations</p></li><li><p>Net loss for Q4 narrowed compared to the previous year</p></li></ul><p><span>Outlook</span></p><ul><li><p>STAAR expects modest growth in China's in-market volume demand in 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CHINA SALES - Growth in China drove overall net sales increase, despite inventory management challenges</p></li><li><p>GROSS MARGIN IMPROVEMENT - Gross margin rose due to cost reductions and timing of cost recognition from previous shipments</p></li></ul><p>Company press release: <span>ID:nBw6WVKSra</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Sales</p></td><td><p>Miss</p></td><td><p>$57.80 mln</p></td><td><p>$75.37 mln (9 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.37</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$18.31 mln</p></td><td></td></tr><tr><td><p>Q4 Gross Margin</p></td><td></td><td><p>75.70%</p></td><td></td></tr><tr><td><p>Q4 Gross Profit</p></td><td></td><td><p>$43.74 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Income</p></td><td></td><td><p>-$22.84 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 10 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for STAAR Surgical Co is $22.00, about 15.5% above its March 2 closing price of $19.05</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>STAAR Surgical Q4 sales miss estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSTAAR Surgical Q4 sales miss estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-04 05:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/STAA\">STAAR Surgical</a> Q4 sales miss estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Vision correction firm's Q4 net sales rose 18.1% yr/yr but missed analyst expectations</p></li><li><p>Net loss for Q4 narrowed compared to the previous year</p></li></ul><p><span>Outlook</span></p><ul><li><p>STAAR expects modest growth in China's in-market volume demand in 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CHINA SALES - Growth in China drove overall net sales increase, despite inventory management challenges</p></li><li><p>GROSS MARGIN IMPROVEMENT - Gross margin rose due to cost reductions and timing of cost recognition from previous shipments</p></li></ul><p>Company press release: <span>ID:nBw6WVKSra</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Sales</p></td><td><p>Miss</p></td><td><p>$57.80 mln</p></td><td><p>$75.37 mln (9 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.37</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$18.31 mln</p></td><td></td></tr><tr><td><p>Q4 Gross Margin</p></td><td></td><td><p>75.70%</p></td><td></td></tr><tr><td><p>Q4 Gross Profit</p></td><td></td><td><p>$43.74 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Income</p></td><td></td><td><p>-$22.84 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 10 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for STAAR Surgical Co is $22.00, about 15.5% above its March 2 closing price of $19.05</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STAA","symbol_name":"STAAR Surgical Company","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL1N3ZR195:1","article_id":"2616371007","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616371007","pubTimestamp":1772572397,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"STAAR Surgical Q4 sales miss estimatesOverviewVision correction firm's Q4 net sales rose 18.1% yr/yr but missed analyst expectationsNet loss for Q4 narrowed compared to the previous yearOutlookSTAAR e","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"STAA":"STAAR Surgical Company","BK4588":"碎股","BK4198":"医疗保健用品","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓"},"translate_title":"STAAR Surgical第四季度销售额未达预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STAA":0.9},"content_text":"STAAR Surgical Q4 sales miss estimatesOverviewVision correction firm's Q4 net sales rose 18.1% yr/yr but missed analyst expectationsNet loss for Q4 narrowed compared to the previous yearOutlookSTAAR expects modest growth in China's in-market volume demand in 2026Result DriversCHINA SALES - Growth in China drove overall net sales increase, despite inventory management challengesGROSS MARGIN IMPROVEMENT - Gross margin rose due to cost reductions and timing of cost recognition from previous shipmentsCompany press release: ID:nBw6WVKSraKey DetailsMetricBeat/MissActualConsensus EstimateQ4 SalesMiss$57.80 mln$75.37 mln (9 Analysts)Q4 EPS-$0.37Q4 Net Income-$18.31 mlnQ4 Gross Margin75.70%Q4 Gross Profit$43.74 mlnQ4 Operating Income-$22.84 mlnAnalyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy\", 10 \"hold\" and 1 \"sell\" or \"strong sell\"The average consensus recommendation for the medical equipment, supplies & distribution peer group is \"buy.\"Wall Street's median 12-month price target for STAAR Surgical Co is $22.00, about 15.5% above its March 2 closing price of $19.05For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616371007","isCrawlerRequest":true}